

Supporting information

Access to (*E*)- δ -Vinyl-Homoallylic Alcohols/Ethers/Pyrazoles by Ring-opening Nucleophilic Substitution of cyclopropyl allylic alcohols

Yulu Zhang, Ying Shao, Jiangtao Sun* and Shengbiao Tang*

E-mail: shengbiaotang@cczu.edu.cn, jtsun@cczu.edu.cn

General information

General procedure A for the preparation of substrates **1**

Table S1-S4

General procedure B for the preparation of **3**

General procedure C for the preparation of **5**

Preparation for the compound of **6-8**

¹H NMR, ¹³C NMR Spectra of all new compounds


General information

All reactions were carried out using oven-dried tube with magnetic stirring under argon atmosphere unless otherwise noted. Anhydrous solvents were dried prior to use. Reagents were purchased from Energy Chemical and used without further purification. For column chromatography, 200-300 mesh silica gel was used. Thin layer chromatography (TLC) was performed on Silicycle 250 μ m silica gel 60Å plates. Visualization was accomplished with UV light (254 nm), Iodine, or Potassium Permanganate.

^1H NMR and ^{13}C NMR spectra were recorded on a Bruker 300 MHz (300 MHz for ^1H ; 282 MHz for ^{19}F ; 75 MHz for ^{13}C) spectrometers at ambient temperature. The chemical shifts (δ) are given in parts per million relative to CDCl_3 (7.26 ppm for ^1H) or TMS (0 ppm for ^1H) and CDCl_3 (77.16 ppm for ^{13}C). Coupling constants (J) are reported in Hz, and multiplicity is described using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, or combinations thereof. HRMS were performed on Agilent 6540 Q-TOF mass spectrometer (ESI).

All pyrazoles/alcohols **2/4** are commercially available, purchased from Energy Chemical and used directly without further purification. All known vinyl cyclopropyl alcohols **1** were prepared according to the reported literatures.¹ The configuration of **1p** was determined by comparing the NMR spectra with the reported literature.² All new compounds have been characterized by ^1H NMR, ^{13}C NMR and HRMS.


General procedure for the preparation of the substrates 1



To a dried 250 mL flask were added CH_2I_2 (20.0 mmol, 2.0 eq.) and CH_2Cl_2 (100 mL). After cooling to 0 °C, Et_2Zn (1 M in hexane, 12.5 mmol, 1.25 eq.) was added. The resulting mixture was stirred at this temperature for 30 min. To another flask were added compound **S-I** (10.0 mmol, 1.0 eq.) and CH_2Cl_2 (30 mL). After cooling to 0 °C, Et_2Zn (1 M in hexane, 12.5 mmol, 1.25 eq.) was added. The resulting mixture was stirred at this temperature for 30 min. This reaction mixture was then added to the reaction mixture in the 250 mL flask. After stirred at 0 °C for 30 min, the resulting mixture was allowed to warm to room temperature and then stirred for 18 h. Then, the reaction mixture was quenched with sat. aq. NH_4Cl and 1 M aq. HCl . The organic layer was separated. The aqueous layer was then extracted with CH_2Cl_2 (2*100 mL). The combined organic layer was dried over MgSO_4 and concentrated in vacuo. The residue was direct used without further purification. To a solution of compound (10.0 mmol) in CH_2Cl_2 (25 mL) was added PCC (15.0 mmol, 1.5 eq.) at room temperature under Ar atmosphere. After 1 h, the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford aldehyde **S-II** as colorless oil.

To a flame dried flask was cooled to 0 °C and charged with compound **S-II** and dry THF (100 mL), the flask was backfilled with argon gas. Then, vinylmagnesium chloride (1.0 M in THF solution, 20.0 mmol, 2.0 eq.) was slowly added to the above solution of compound **S-II**. Then, the mixture was stirred at 0 °C for 1 h (monitored by TLC) and quenched with saturated aq. NH_4Cl (50 mL). The aqueous layer was extracted with EtOAc (50*3) and the organic phase was dried with Na_2SO_4 , filtered and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel to give the diastereoisomer **1/1'** = 1:1. The new compounds as listed below:

1-(2-Phenylcyclopropyl)prop-2-en-1-ol (**1a**+**1a'**)



The title compound was prepared from the general procedure A, 3-phenylprop-2-en-1-ol (1.34 g, 10.0 mmol, 1.0 eq.), CH_2I_2 (5.36 g, 20.0 mmol, 2.0 eq.), Et_2Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1a** (696.4 mg, 40% yield over two steps) and **1a'** (696.0 mg, 40% yield over two steps) as colorless oil.

NMR data of **1a**:

^1H NMR (300 MHz, CDCl_3) δ 7.35-7.00 (m, 5H), 6.12-5.87 (m, 1H), 5.28 (d, J = 17.2 Hz, 1H), 5.14 (d, J = 10.5 Hz, 1H), 3.76 (t, J = 6.6 Hz, 1H), 1.87 (dt, J = 8.7, 5.0 Hz, 1H), 1.78 (s, 1H), 1.40-1.27 (m, 1H), 1.12-0.94 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 142.5, 139.4, 128.5, 126.0, 125.8, 115.2, 76.1, 28.9, 21.3, 13.0.


NMR data of **1a'**:

^1H NMR (300 MHz, CDCl_3) δ 7.37-6.97 (m, 5H), 6.10-5.85 (m, 1H), 5.30 (d, J = 17.2 Hz, 1H), 5.15 (d, J = 10.5 Hz, 1H), 3.77 (t, J = 6.7 Hz, 1H), 1.96 (dt, J = 8.5, 5.1 Hz, 1H), 1.76 (s, 1H), 1.41-1.29 (m, 1H), 1.04-0.90 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 142.3, 139.6, 128.5, 126.1, 125.8, 115.2, 76.1, 28.7, 20.5, 13.7.

HRMS (ESI) m/z calculated for C₁₂H₁₅O [M+H]⁺: 175.1117, found: 175.1119.

1-(2-(*p*-Tolyl)cyclopropyl)prop-2-en-1-ol (1b)




The title compound was prepared from the general procedure A, 3-(*p*-tolyl)prop-2-en-1-ol (1.48 g, 10.0 mmol, 1 eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2 eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1b** (790.1 mg, 42% yield over two steps) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.04 (d, *J* = 7.7 Hz, 2H), 6.94 (d, *J* = 7.8 Hz, 2H), 6.08-5.85 (m, 1H), 5.25 (d, *J* = 17.3 Hz, 1H), 5.10 (d, *J* = 10.5 Hz, 1H), 3.69 (t, *J* = 6.7 Hz, 1H), 2.37 (s, 1H), 2.28 (s, 3H), 1.80 (dt, *J* = 9.5, 5.0 Hz, 1H), 1.33-1.21 (m, 1H), 1.07-0.88 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 139.6, 139.2, 135.1, 129.0, 125.9, 114.9, 76.0, 28.4, 21.0, 20.1, 13.5.

HRMS (ESI) m/z calculated for C₁₃H₁₇O [M+H]⁺: 189.1274, found: 189.1273.

1-(2-(4-Isopropylphenyl)cyclopropyl)prop-2-en-1-ol (1c)




The title compound was prepared from the general procedure A, 3-(4-isopropylphenyl)prop-2-en-1-ol (1.76 g, 10.0 mmol, 1 eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2 eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1c** (864.6 mg, 40% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.05 (d, *J* = 7.9 Hz, 2H), 6.93 (d, *J* = 7.8 Hz, 2H), 6.04-5.80 (m, 1H), 5.21 (d, *J* = 17.2 Hz, 1H), 5.06 (d, *J* = 10.4 Hz, 1H), 3.67 (t, *J* = 6.8 Hz, 1H), 2.79 (p, *J* = 7.0 Hz, 1H), 1.78 (dt, *J* = 9.5, 5.1 Hz, 1H), 1.62 (s, 1H), 1.30-1.20 (m, 1H), 1.16 (s, 3H), 1.14 (s, 3H), 1.02-0.82 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 146.5, 139.61, 139.57, 126.5, 126.1, 115.2, 76.3, 33.8, 28.6, 24.2, 20.2, 13.6.

HRMS (ESI) m/z calculated for C₁₅H₂₁O [M+H]⁺: 217.1587, found: 217.1580.

1-(2-(4-Methoxyphenyl)cyclopropyl)prop-2-en-1-ol (1d)




The title compound was prepared from the general procedure A, 3-(4-methoxyphenyl)prop-2-en-1-ol (1.64 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1d** (898.1 mg, 44% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 6.99 (d, *J* = 8.5 Hz, 2H), 6.80 (d, *J* = 8.6 Hz, 2H), 6.08-5.88 (m, 1H), 5.27 (d, *J* = 17.3 Hz, 1H), 5.13 (d, *J* = 9.9 Hz, 1H), 3.80-3.69 (m, 1H), 3.76 (s, 3H), 2.00-1.87 (m, 1H), 1.87-1.76 (m, 1H), 1.33-1.16 (m, 1H), 1.07-0.80 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 157.9, 139.6, 134.2, 127.2, 115.1, 113.9, 76.3, 55.4, 28.3, 19.8, 13.3.

HRMS (ESI) *m/z* calculated for C₁₃H₁₇O₂ [M+H]⁺: 205.1223, found: 205.1225.

1-(2-(2,4-Dimethylphenyl)cyclopropyl)prop-2-en-1-ol (1e)




The title compound was prepared from the general procedure A, 3-(2,4-dimethylphenyl)prop-2-en-1-ol (1.62 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1e** (849.0 mg, 42% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.02-6.64 (m, 3H), 6.09-5.76 (m, 1H), 5.19 (d, *J* = 17.2 Hz, 1H), 5.04 (d, *J* = 10.5 Hz, 1H), 3.66 (t, *J* = 6.9 Hz, 1H), 2.38-2.03 (m, 1H), 2.25 (s, 3H), 2.17 (s, 3H), 1.74 (d, *J* = 8.5 Hz, 1H), 1.28-1.07 (m, 1H), 0.99-0.69 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 139.8, 137.3, 136.7, 135.4, 130.6, 126.5, 125.6, 115.1, 76.3, 26.9, 20.9, 19.8, 18.1, 11.8.

HRMS (ESI) *m/z* calculated for C₁₄H₁₉O [M+H]⁺: 203.1430, found: 203.1437.

1-(2-(2-(Benzyloxy)phenyl)cyclopropyl)prop-2-en-1-ol (1f)




The title compound was prepared from the general procedure A, 3-(2-(benzyloxy)phenyl)prop-2-en-1-ol (2.40 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1f** (1.15 g, 41% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.45-7.22 (m, 5H), 7.05 (t, *J* = 7.6 Hz, 1H), 6.91-6.75 (m, 3H), 5.86-5.68 (m, 1H), 5.18-4.91 (m, 4H), 3.85 (t, *J* = 6.2 Hz, 1H), 2.12-1.84 (m, 2H), 1.24-1.09 (m, 1H), 1.02-0.81 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 157.5, 138.9, 137.1, 130.6, 128.7, 128.2, 127.7, 126.9, 126.4, 121.0, 115.0, 111.7, 74.8, 70.4, 27.7, 14.3, 11.0.

HRMS (ESI) *m/z* calculated for C₁₉H₂₁O₂ [M+H]⁺: 281.1536, found: 281.1539.

1-(2-(2-Methoxyphenyl)cyclopropyl)prop-2-en-1-ol (1g)




The title compound was prepared from the general procedure A, 3-(2-methoxyphenyl)prop-2-en-1-ol (1.64 g, 10.0 mmol, 1 eq.), CH_2I_2 (5.36 g, 20.0 mmol, 2.0 eq.), Et_2Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1g** (714.4 mg, 35% yield over two steps) as colorless oil.

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.02 (m, 1H), 6.91-6.71 (m, 3H), 5.96-5.73 (m, 1H), 5.25 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.3 Hz, 1H), 3.94 (t, J = 6.3 Hz, 1H), 3.78 (s, 3H), 2.28 (s, 1H), 1.96 (dt, J = 8.8, 5.5 Hz, 1H), 1.24-1.11 (m, 1H), 0.99-0.84 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 158.3, 138.9, 130.2, 127.0, 126.5, 120.7, 115.1, 110.2, 74.7, 55.5, 27.2, 14.1, 11.1.

HRMS (ESI) m/z calculated for $\text{C}_{13}\text{H}_{17}\text{O}_2$ $[\text{M}+\text{H}]^+$: 205.1223, found: 205.1225.

1-(2-(4-Chlorophenyl)cyclopropyl)prop-2-en-1-ol (1h)




The title compound was prepared from the general procedure A, 3-(4-chlorophenyl)prop-2-en-1-ol (1.68 g, 10.0 mmol, 1 eq.), CH_2I_2 (5.36 g, 20.0 mmol, 2.0 eq.), Et_2Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1h** (811.5 mg, 39% yield over two steps) as colorless oil.

^1H NMR (300 MHz, CDCl_3) δ 7.28-7.17 (m, 2H), 7.01 (d, J = 8.5 Hz, 2H), 6.07-5.88 (m, 1H), 5.30 (d, J = 17.2 Hz, 1H), 5.17 (d, J = 10.4 Hz, 1H), 3.78 (t, J = 6.7 Hz, 1H), 1.95 (dt, J = 9.3, 5.0 Hz, 1H), 1.67 (s, 1H), 1.34-1.24 (m, 1H), 1.05-0.86 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 141.1, 139.3, 131.4, 128.5, 127.4, 115.4, 75.9, 28.9, 20.8, 13.0.

HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{14}\text{ClO}$ $[\text{M}+\text{H}]^+$: 209.0728, found: 209.0723.

1-(2-(4-(Trifluoromethyl)phenyl)cyclopropyl)prop-2-en-1-ol (1i)



The title compound was prepared from the general procedure A, 3-(4-(trifluoromethyl)phenyl)prop-2-en-1-ol (2.02 g, 1 eq.), CH_2I_2 (5.36 g, 20.0 mmol, 2.0 eq.), Et_2Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1i** (798.9 mg, 33% yield over two steps) as colorless oil.


¹H NMR (300 MHz, CDCl₃) δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 6.11-5.86 (m, 1H), 5.29 (d, *J* = 17.2 Hz, 1H), 5.16 (d, *J* = 10.4 Hz, 1H), 3.83 (t, *J* = 6.6 Hz, 1H), 1.93 (dt, *J* = 9.4, 5.0 Hz, 1H), 1.77 (s, 1H), 1.46-1.30 (m, 1H), 1.22-0.99 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 146.7, 139.3, 128.1 (q, *J* = 32.4 Hz), 126.2, 125.40 (q, *J* = 3.8 Hz), 122.6, 115.6, 75.6, 29.4, 20.3, 14.2.

¹⁹F NMR (282 MHz, CDCl₃) δ -62.3.

HRMS (ESI) *m/z* calculated for C₁₃H₁₄F₃O [M+H]⁺: 243.0991, found: 243.0994.

1-(2-(2-Bromophenyl)cyclopropyl)prop-2-en-1-ol (1j)




The title compound was prepared from the general procedure A, 3-(2-bromophenyl)prop-2-en-1-ol (2.12 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1j** (806.4 mg, 32% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.53 (d, *J* = 8.0 Hz, 1H), 7.36-6.80 (m, 3H), 6.24-5.85 (m, 1H), 5.32 (d, *J* = 17.2 Hz, 1H), 5.16 (d, *J* = 10.5 Hz, 1H), 3.96 (t, *J* = 6.3 Hz, 1H), 2.39-1.90 (m, 2H), 1.42-1.19 (m, 1H), 1.19-0.89 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 141.0, 139.4, 132.6, 127.5, 127.4, 126.8, 125.8, 115.3, 75.0, 28.2, 20.8, 12.2.

HRMS (ESI) *m/z* calculated for C₁₂H₁₄BrO [M+H]⁺: 253.0223, found: 253.0227.

1-(2-(2-Bromo-4,5-dimethoxyphenyl)cyclopropyl)prop-2-en-1-ol (1k)




The title compound was prepared from the general procedure A, 3-(2-bromo-4,5-dimethoxyphenyl)prop-2-en-1-ol (2.72 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1k** (1.06 g, 34% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.02 (s, 1H), 6.45 (s, 1H), 6.12-5.94 (m, 1H), 5.32 (d, *J* = 17.2 Hz, 1H), 5.17 (d, *J* = 10.5 Hz, 1H), 3.97 (t, *J* = 6.3 Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 2.11 (dt, *J* = 8.5, 5.2 Hz, 1H), 2.01 (s, 1H), 1.32-1.20 (m, 1H), 1.15-1.02 (m, 1H), 1.01-0.90 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 148.5, 147.9, 139.4, 132.9, 115.6, 115.5, 115.3, 110.1, 74.9, 56.3, 56.1, 28.0, 20.5, 12.0.

HRMS (ESI) *m/z* calculated for C₁₄H₁₈BrO₃ [M+H]⁺: 313.0434, found: 313.0437.

1-(2-(Naphthalen-2-yl)cyclopropyl)prop-2-en-1-ol (1l)




The title compound was prepared from the general procedure A, 3-(naphthalen-2-yl)prop-2-en-1-ol (1.84 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1l** (851.7 mg, 38% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.83-7.68 (m, 3H), 7.56-7.34 (m, 3H), 7.17 (d, *J* = 8.5 Hz, 1H), 6.11-5.91 (m, 1H), 5.30 (d, *J* = 16.3 Hz, 1H), 5.15 (d, *J* = 10.8 Hz, 1H), 3.80 (t, *J* = 6.7 Hz, 1H), 2.09-1.98 (m, 1H), 1.86 (s, 1H), 1.50-1.35 (m, 1H), 1.21-1.04 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 139.8, 139.5, 133.6, 132.1, 128.1, 127.7, 127.4, 126.2, 125.2, 124.9, 124.2, 115.3, 76.1, 28.8, 20.7, 13.7.

HRMS (ESI) *m/z* calculated for C₁₆H₁₇O [M+H]⁺: 225.1274, found: 225.1279.

1-(2-(6-Bromobenzo[d][1,3]dioxol-5-yl)cyclopropyl)prop-2-en-1-ol (1m)




The title compound was prepared from the general procedure A, 3-(6-bromobenzo[d][1,3]dioxol-5-yl)prop-2-en-1-ol (2.56 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1m** (1.27 g, 43% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.00 (s, 1H), 6.46 (s, 1H), 6.07-5.92 (m, 1H), 5.93 (s, 2H), 5.32 (dt, *J* = 17.3, 1.5 Hz, 1H), 5.17 (dt, *J* = 10.4, 1.4 Hz, 1H), 4.04-3.86 (m, 1H), 2.09 (dt, *J* = 8.8, 5.2 Hz, 1H), 1.81 (d, *J* = 4.4 Hz, 1H), 1.30-1.17 (m, 1H), 1.14-1.01 (m, 1H), 0.95-0.84 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 147.5, 146.6, 139.3, 134.2, 115.9, 115.4, 112.7, 107.2, 101.7, 75.0, 28.1, 20.9, 12.1.

HRMS (ESI) *m/z* calculated for C₁₃H₁₄BrO₃ [M+H]⁺: 297.0121, found: 297.0118.

1-(2-Phenylcyclopropyl)propan-1-ol (1p)



The title compound was prepared from the general procedure A, 3-phenylprop-2-en-1-ol (1.34 g, 10.0 mmol, 1eq.), CH₂I₂ (5.36 g, 20.0 mmol, 2.0 eq.), Et₂Zn (1 M in hexane, 12.5 mL, 1.25 eq.), vinylmagnesium chloride (1.0 M in THF, 20.0 mL, 2eq.) was used. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **1p** (845.4 mg, 48% yield over two steps) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.31-7.21 (m, 2H), 7.20-7.11 (m, 1H), 7.11-7.00 (m, 2H), 3.08 (dt, *J* = 8.1, 6.3 Hz, 1H), 1.82 (dt, *J* = 9.2, 5.0 Hz, 1H), 1.74-1.61 (m, 3H), 1.30-1.17 (m, 1H), 1.06-0.91 (m, 5H).

¹³C NMR (75 MHz, CDCl₃) δ 142.5, 128.5, 125.9, 125.7, 77.2, 30.4, 29.5, 21.3, 13.3, 10.3.

The NMR data was consistent with the reported literature.²


Table S1. Screening of the Bronsted acids to **3aa**

entry	Cat. (mol%)	Yield (%)
1	TfOH (1eq.)	15%
2	TfOH(50 mol%)	trace
3	HBr (50 mol%)	trace
4	AcOH (50 mol%)	0%
5	PhCO ₂ H (50 mol%)	0%
6	TsOH (50 mol%)	50%
7	TsOH (1eq.)	61%
8	TFA (50 mol%)	45%

Table S2. Screening of the Bronsted acids to **5a**


entry	Cat. (mol%)	Yield (%)
1	TfOH (1eq.)	55%
2	TfOH(50 mol%)	30%
3	HBr (50 mol%)	12%
4	AcOH (50 mol%)	trace
5	PhCO ₂ H (50 mol%)	trace
6	TsOH (1 eq.)	51
7	TFA (1 eq.)	46

Table S3. Testing of the loading of catalyst for the synthesis of **3aa**




entry	Yb(OTf) ₃ (xx mol%)	Yield (%)
1	10 mol%, 24 h	80
2	15 mol%, 24 h	82
3	20 mol%, 12 h	82
4	50 mol%, 6 h	82

Table S4. Testing of the loading of catalyst for the synthesis of **5a**




entry	Ga(OTf) ₃ (xx mol%)	Yield of 5a (%)
1	10 mol%, 24 h	20%
2	20 mol%, 24 h	42%
3	30 mol%, 24 h	65%
4	50 mol%, 12 h	65%
5	60 mol%, 12 h	64%

General procedure B for synthesis of 3aa-3na, 3ab-3aj



General procedure B: A 10 mL dry tube equipped with a stir bar was charged with allylic alcohols **1** (0.1 mmol, 1.0 eq.), pyrazoles **2** (0.15 mmol, 1.5 eq.), Yb(OTf)₃ (15 mol%) and dry DCE (2.0 mL). The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, then 2.0 ml of water was added, and the reaction solution was extracted with ethyl acetate (3 x 5 mL), the combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel to afford the corresponding products (**3aa-3na**, **3ab-3aj**).

(E)-4-Nitro-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole (3aa)



The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3aa** (22.1 mg, 82%)


yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.03 (s, 1H), 8.02 (s, 1H), 7.38-7.21 (m, 5H), 6.23-5.95 (m, 2H), 5.42 (dt, *J* = 14.3, 7.1 Hz, 1H), 5.23 (t, 1H), 5.14-4.88 (m, 2H), 3.17 (dt, *J* = 15.6, 8.1 Hz, 1H), 2.89 (dt, *J* = 14.2, 6.8 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 137.9, 136.3, 135.9, 135.8, 135.1, 129.3, 129.1, 128.1, 127.9, 127.2, 117.4, 67.8, 38.0.

HRMS (ESI) *m/z* calculated for C₁₅H₁₆N₃O₂ [M+H]⁺: 270.1237, found: 270.1238.

***(E)*-4-Nitro-1-(1-(*p*-tolyl)hexa-3,5-dien-1-yl)-1H-pyrazole (3ba)**




The title compound was prepared from **1b** (18.8 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ba** (22.7 mg, 80% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.09 (s, 1H), 8.05 (s, 1H), 7.26-7.16 (m, 4H), 6.33-6.01 (m, 2H), 5.48 (dt, *J* = 14.4, 7.2 Hz, 1H), 5.27 (t, 1H), 5.12 (d, *J* = 16.1 Hz, 1H), 5.03 (d, *J* = 10.4 Hz, 1H), 3.22 (dt, *J* = 15.1, 8.0 Hz, 1H), 3.03-2.88 (m, 1H), 2.35 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 139.2, 136.4, 135.9, 135.0, 134.8, 130.0, 128.1, 127.9, 127.2, 117.4, 67.5, 37.9, 21.3.

HRMS (ESI) *m/z* calculated for C₁₆H₁₈N₃O₂ [M+H]⁺: 280.1394, found: 280.1390.

***(E)*-1-(1-(4-Isopropylphenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ca)**




The title compound was prepared from **1c** (21.6 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:15) furnished **3ca** (24.0 mg, 77% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 8.01 (d, *J* = 6.2 Hz, 2H), 7.17 (s, 4H), 6.26-5.93 (m, 2H), 5.51-5.32 (m, 1H), 5.21 (t, 1H), 5.04 (d, *J* = 16.2 Hz, 1H), 4.95 (d, *J* = 10.3 Hz, 1H), 3.15 (dt, *J* = 15.7, 8.1 Hz, 1H), 2.97-2.75 (m, 2H), 1.17 (d, *J* = 7.0 Hz, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 150.0, 136.4, 135.8, 135.2, 135.0, 128.1, 128.0, 127.34, 127.29, 127.2, 117.3, 67.6, 37.9, 33.9, 24.0.

HRMS (ESI) *m/z* calculated for C₁₈H₂₂N₃O₂ [M+H]⁺: 312.1707, found: 312.1710.

***(E)*-1-(1-(4-Methoxyphenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3da)**




The title compound was prepared from **1d** (20.4 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3da** (21.2 mg, 71% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.09 (s, 1H), 8.04 (s, 1H), 7.28 (d, *J* = 8.7 Hz, 2H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.34-5.98 (m, 2H), 5.48 (dt, *J* = 14.3, 7.1 Hz, 1H), 5.25 (t, *J* = 7.7 Hz, 1H), 5.12 (d, *J* = 16.5 Hz, 1H), 5.03 (d, *J* = 10.4 Hz, 1H), 3.81 (s, 3H), 3.22 (dt, *J* = 15.2, 7.9 Hz, 1H), 2.94 (dt, *J* = 14.3, 7.0 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 160.1, 136.4, 135.9, 135.0, 129.7, 128.8, 128.7, 128.1, 127.8, 117.4, 114.6, 67.2, 55.5, 38.0.

HRMS (ESI) *m/z* calculated for C₁₆H₁₈N₃O₃ [M+H]⁺: 300.1343, found: 300.1348.

(E)-1-(1-(2,4-Dimethylphenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ea)




The title compound was prepared from **1e** (20.2 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ea** (21.4 mg, 72% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 8.08 (s, 1H), 7.93 (s, 1H), 7.33-7.24 (m, 1H), 7.13-7.01 (m, 2H), 6.32-6.04 (m, 2H), 5.64-5.45 (m, 2H), 5.13 (d, *J* = 15.6 Hz, 1H), 5.03 (d, *J* = 8.9 Hz, 1H), 3.18 (dt, *J* = 15.3, 7.8 Hz, 1H), 2.93 (dt, *J* = 14.5, 7.0 Hz, 1H), 2.32 (s, 3H), 2.25 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 139.1, 136.5, 136.4, 135.7, 134.9, 132.3, 132.2, 128.2, 127.7, 127.6, 126.3, 117.3, 63.5, 37.7, 21.2, 19.3.

HRMS (ESI) *m/z* calculated for C₁₇H₂₀N₃O₂ [M+H]⁺: 298.1550, found: 298.1557.

(E)-1-(1-(2-(Benzyloxy)phenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3fa)




The title compound was prepared from **1f** (28.0 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3fa** (29.3 mg, 78% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 8.08 (s, 1H), 8.01 (s, 1H), 7.51-7.31 (m, 7H), 7.12-6.98 (m, 2H), 6.33-6.00 (m, 2H), 5.74 (dd, *J* = 9.1, 6.1 Hz, 1H), 5.51 (dt, *J* = 14.5, 7.1 Hz, 1H), 5.18-4.96 (m, 4H), 3.25 (dt, *J* = 15.9, 8.3 Hz, 1H), 2.98 (dt, *J* = 14.0, 6.6 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 155.9, 136.4, 136.1, 135.8, 135.1, 134.8, 130.2, 129.1, 129.0, 128.6, 128.5, 127.9, 127.7, 126.1, 121.3, 117.1, 112.2, 70.6, 61.1, 36.2.

HRMS (ESI) *m/z* calculated for C₂₂H₂₂N₃O₃ [M+H]⁺: 376.1656, found: 376.1659.

(E)-1-(1-(2-Methoxyphenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ga)




The title compound was prepared from **1g** (20.4 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ga** (20.3 mg, 68% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.05 (s, 1H), 7.99 (s, 1H), 7.36-7.21 (m, 2H), 6.92 (t, *J* = 7.6 Hz, 1H), 6.84 (d, *J* = 8.2 Hz, 1H), 6.23-5.93 (m, 2H), 5.69 (dd, *J* = 9.2, 6.2 Hz, 1H), 5.44 (dt, *J* = 14.4, 7.1 Hz, 1H), 5.04 (d, *J* = 17.1 Hz, 1H), 4.94 (d, *J* = 9.6 Hz, 1H), 3.77 (s, 3H), 3.17 (dt, *J* = 15.9, 8.4 Hz, 1H), 2.86 (dt, *J* = 14.0, 6.5 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 156.7, 136.5, 135.8, 134.7, 130.2, 128.7, 128.6, 127.6, 126.0, 121.1, 117.1, 111.0, 60.9, 55.7, 36.5.

HRMS (ESI) *m/z* calculated for C₁₆H₁₈N₃O₃ [M+H]⁺: 300.1343, found: 300.1348.

(E)-1-(1-(4-Chlorophenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ha)




The title compound was prepared from **1h** (20.8 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ha** (16.7 mg, 55% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 8.10 (s, 1H), 7.47-7.22 (m, 4H), 6.47-5.88 (m, 2H), 5.62-5.32 (m, 1H), 5.36-4.93 (m, 3H), 3.34-3.08 (m, 1H), 3.05-2.83 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 136.5, 136.2, 136.1, 135.4, 135.1, 129.5, 128.6, 128.0, 127.4, 117.7, 67.1, 38.0.

HRMS (ESI) *m/z* calculated for C₁₅H₁₅ClN₃O₂ [M+H]⁺: 304.0847, found: 304.0851.

(E)-4-Nitro-1-(1-(4-(trifluoromethyl)phenyl)hexa-3,5-dien-1-yl)-1H-pyrazole (3ia)



The title compound was prepared from **1i** (24.2 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:5) furnished **3ia** (15.5 mg, 46% yield) as yellow oil.


¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 8.13 (s, 1H), 7.65 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 7.8 Hz, 2H), 6.34-5.99 (m, 2H), 5.47 (dt, *J* = 14.3, 7.2 Hz, 1H), 5.41-5.27 (m, 1H), 5.24-4.99 (m, 2H), 3.25 (dt, *J* = 15.7, 8.2 Hz, 1H), 2.97 (dt, *J* = 14.1, 6.7 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 142.0, 136.2, 136.1, 135.6, 128.2, 127.6, 127.5, 127.1, 126.3 (q, *J* = 3.7 Hz), 123.1 (q, *J* = 245.2 Hz), 120.1, 118.0, 67.3, 38.0.

¹⁹F NMR (282 MHz, CDCl₃) δ -62.8.

HRMS (ESI) *m/z* calculated for C₁₆H₁₅F₃N₃O₂ [M+H]⁺: 338.1111, found: 338.1115.

(E)-1-(1-(2-Bromophenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ja)




The title compound was prepared from **1j** (25.2 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.5 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ja** (17.7 mg, 51% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.19 (s, 1H), 8.12 (s, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.54-7.16 (m, 3H), 6.40-5.94 (m, 2H), 5.80 (t, 1H), 5.53 (dt, *J* = 14.4, 7.3 Hz, 1H), 5.29-4.89 (m, 2H), 3.25 (dt, *J* = 16.5, 8.2 Hz, 1H), 3.07-2.82 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 137.2, 136.3, 136.2, 135.3, 133.5, 130.5, 129.1, 128.4, 127.6, 117.6, 66.0, 37.2.

HRMS (ESI) *m/z* calculated for C₁₅H₁₅BrN₃O₂ [M+H]⁺: 348.0342, found: 348.0340.

(E)-1-(1-(2-Bromo-4,5-dimethoxyphenyl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ka)




The title compound was prepared from **1k** (31.2 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ka** (26.1 mg, 64% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 8.17 (s, 1H), 8.12 (s, 1H), 7.03 (s, 2H), 6.34-6.01 (m, 2H), 5.79-5.65 (m, 1H), 5.60-5.41 (m, 1H), 5.13 (d, *J* = 16.3 Hz, 1H), 5.04 (d, *J* = 8.6 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.37-3.15 (m, 1H), 3.02-2.81 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 150.0, 149.1, 136.3, 136.1, 135.6, 135.2, 129.02, 128.96, 127.7, 117.5, 115.5, 114.1, 110.7, 65.7, 56.34, 56.30, 37.5.

HRMS (ESI) *m/z* calculated for C₁₇H₁₉BrN₃O₄ [M+H]⁺: 408.0553, found: 408.0558.

(E)-1-(1-(Naphthalen-2-yl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3la)




The title compound was prepared from **1l** (22.4 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:15) furnished **3la** (19.2 mg, 60% yield) as yellow solid.

¹H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 8.11 (s, 1H), 7.96-7.73 (m, 4H), 7.52 (dd, *J* = 6.3, 3.3 Hz, 2H), 7.43 (d, *J* = 8.4 Hz, 1H), 6.39-5.99 (m, 2H), 5.63-5.40 (m, 2H), 5.13 (d, *J* = 15.3 Hz, 1H), 5.03 (d, *J* = 10.2 Hz, 1H), 3.34 (dt, *J* = 15.5, 8.0 Hz, 1H), 3.08 (dt, *J* = 14.0, 6.7 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 136.3, 135.9, 135.2, 133.4, 133.3, 129.4, 128.3, 128.1, 127.9, 127.0, 126.9, 126.7, 124.4, 117.5, 67.9, 37.9.

HRMS (ESI) *m/z* calculated for C₁₉H₁₈N₃O₂ [M+H]⁺: 320.1394, found: 320.1390.

(E)-1-(1-(6-Bromobenzo[d][1,3]dioxol-5-yl)hexa-3,5-dien-1-yl)-4-nitro-1H-pyrazole (3ma)




The title compound was prepared from **1m** (29.6 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ma** (25.4 mg, 65% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.17 (s, 1H), 8.11 (s, 1H), 7.02 (s, 1H), 6.98 (s, 1H), 6.34-6.06 (m, 2H), 6.01 (d, *J* = 13.5 Hz, 2H), 5.72 (dd, *J* = 9.1, 6.0 Hz, 1H), 5.49 (dt, *J* = 14.5, 7.2 Hz, 1H), 5.14 (d, *J* = 16.6 Hz, 1H), 5.05 (d, *J* = 9.9 Hz, 1H), 3.20 (dt, *J* = 15.8, 8.1 Hz, 1H), 2.87 (dt, *J* = 13.9, 6.6 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 148.9, 148.2, 136.3, 136.1, 135.6, 135.2, 130.2, 128.9, 127.5, 117.6, 114.6, 113.0, 107.9, 102.4, 65.8, 37.4.

HRMS (ESI) m/z calculated for C₁₆H₁₅BrN₃O₄ [M+H]⁺: 392.0240, found: 392.0245.

(E)-1-(1,4-Diphenylbut-3-en-1-yl)-4-nitro-1H-pyrazole (3na)




The title compound was prepared from **1n** (22.4 mg, 0.1 mmol, 1 eq.) and **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **3na** (15.0 mg, 47% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 8.04 (s, 2H), 7.40-7.23 (m, 5H), 7.23-7.11 (m, 5H), 6.40 (d, *J* = 15.8 Hz, 1H), 5.93 (dt, *J* = 16.1, 7.1 Hz, 1H), 5.31 (dd, *J* = 8.6, 6.7 Hz, 1H), 3.30 (dt, *J* = 15.5, 8.0 Hz, 1H), 3.02 (dt, *J* = 14.1, 6.7 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 138.0, 136.8, 135.9, 134.3, 129.3, 129.2, 128.7, 128.1, 127.9, 127.2, 126.3, 123.9, 68.0, 38.4.

HRMS (ESI) m/z calculated for C₁₉H₁₈N₃O₂ [M+H]⁺: 320.1394, found: 320.1399.

Methyl (E)-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole-3-carboxylate (3ab)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2b** (18.9 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ab** (14.7 mg, 52% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 7.50 (s, 1H), 7.32 (d, *J* = 7.3 Hz, 2H), 7.29-7.15 (m, 3H), 6.75 (s, 1H), 6.40 (dd, *J* = 9.5, 6.0 Hz, 1H), 6.21-5.90 (m, 2H), 5.45 (dt, *J* = 14.4, 7.1 Hz, 1H), 4.99 (d, *J* = 16.3 Hz, 1H), 4.88 (d, *J* = 9.5 Hz, 1H), 3.76 (s, 3H), 3.26 (dt, *J* = 15.9, 8.2 Hz, 1H), 2.85 (dt, *J* = 13.9, 6.5 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 160.4, 140.7, 138.4, 137.0, 133.9, 132.4, 130.1, 128.6, 127.9, 127.3, 116.2, 111.8, 63.3, 52.0, 38.9.

HRMS (ESI) m/z calculated for C₁₇H₁₉N₂O₂ [M+H]⁺: 283.1441, found: 283.1443.

Ethyl (E)-3-methyl-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole-5-carboxylate (3ac)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2c** (23.1 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ac** (20.2 mg, 65% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.46-7.19 (m, 5H), 6.60 (s, 1H), 6.38 (dd, *J* = 9.3, 6.2 Hz, 1H), 6.28-5.96 (m, 2H), 5.52 (dt, *J* = 14.6, 7.1 Hz, 1H), 5.06 (d, *J* = 16.7 Hz, 1H), 4.95 (d, *J* = 10.0 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 3.29 (dt, *J* = 15.5, 8.2 Hz, 1H), 2.91 (dt, *J* = 14.0, 6.8 Hz, 1H), 2.30 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 160.1, 147.4, 141.1, 137.1, 133.7, 133.2, 130.6, 128.5, 127.7, 127.3, 115.9, 111.1, 62.9, 60.9, 38.9, 14.3, 13.8.

HRMS (ESI) *m/z* calculated for C₁₉H₂₃N₂O₂ [M+H]⁺: 311.1754, found: 311.1750.

Ethyl (E)-5-(tert-butyl)-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole-3-carboxylate (3ad)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2d** (29.4 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ad** (21.1 mg, 60% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 7.2 Hz, 2H), 7.32-7.21 (m, 3H), 6.65 (s, 1H), 6.34 (dd, *J* = 9.9, 5.6 Hz, 1H), 6.28-5.97 (m, 2H), 5.52 (dt, *J* = 14.8, 7.2 Hz, 1H), 5.04 (d, *J* = 16.8 Hz, 1H), 4.93 (d, *J* = 9.9 Hz, 1H), 4.36-4.17 (m, 2H), 3.35 (dt, *J* = 14.3, 8.6 Hz, 1H), 2.81 (dt, *J* = 13.6, 6.4 Hz, 1H), 1.33 (s, 12H).

¹³C NMR (101 MHz, CDCl₃) δ 160.3, 141.5, 137.1, 133.9, 132.4, 130.7, 128.4, 127.6, 127.3, 126.3, 115.8, 107.6, 63.3, 60.8, 39.6, 32.3, 30.60, 30.57, 14.4.

HRMS (ESI) *m/z* calculated for C₂₂H₂₉N₂O₂ [M+H]⁺: 353.2224, found: 353.2227.

Ethyl (E)-5-phenyl-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole-3-carboxylate (3ae)



The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2e** (32.4 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ae** (23.1 mg, 62% yield) as yellow oil.


yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.93-7.82 (m, 2H), 7.49-7.37 (m, 4H), 7.36-7.21 (m, 4H), 7.13 (s, 1H), 6.45 (dd, *J* = 9.4, 5.9 Hz, 1H), 6.28-6.04 (m, 2H), 5.58 (dt, *J* = 14.5, 7.1 Hz, 1H), 5.05 (d, *J* = 15.6 Hz, 1H), 4.94 (d, *J* = 9.1 Hz, 1H), 4.38-4.24 (m, 2H), 3.43 (dt, 1H), 2.95 (dt, 1H), 1.35 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 159.9, 149.9, 140.9, 137.0, 133.9, 133.1, 130.5, 128.8, 128.6, 128.1, 127.8, 127.4, 125.8, 116.1, 108.5, 63.8, 61.1, 39.3, 14.4.

HRMS (ESI) *m/z* calculated for C₂₄H₂₅N₂O₂ [M+H]⁺: 373.1911, found: 373.1910.

Diethyl (E)-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole-3,5-dicarboxylate (3af)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2f** (31.8 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3af** (25.8 mg, 70% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, *J* = 6.6 Hz, 2H), 7.36-7.21 (m, 4H), 6.50 (dd, *J* = 9.1, 6.3 Hz, 1H), 6.26-6.02 (m, 2H), 5.51 (dt, *J* = 14.5, 7.1 Hz, 1H), 5.07 (d, *J* = 15.8 Hz, 1H), 4.96 (d, *J* = 9.0 Hz, 1H), 4.41 (q, *J* = 7.1 Hz, 2H), 4.37-4.24 (m, 2H), 3.40 (dt, *J* = 15.6, 8.2 Hz, 1H), 2.98 (dt, *J* = 14.1, 6.8 Hz, 1H), 1.40 (t, *J* = 7.1 Hz, 3H), 1.34 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 161.9, 159.3, 142.5, 139.8, 136.8, 134.2, 133.9, 129.7, 128.6, 128.1, 127.5, 116.3, 114.4, 64.5, 61.4, 61.2, 38.8, 14.5, 14.2.

HRMS (ESI) *m/z* calculated for C₂₁H₂₅N₂O₄ [M+H]⁺: 369.1809, found: 369.1807.

(E)-4-Bromo-3-methyl-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole (3ag)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2g** (24.0 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ag** (23.7 mg, 75% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 7.33-7.12 (m, 6H), 6.25-5.95 (m, 2H), 5.43 (dt, *J* = 14.4, 7.1 Hz, 1H), 5.19-5.08 (m, 1H), 5.03 (d, *J* = 15.6 Hz, 1H), 4.92 (d, *J* = 9.5 Hz, 1H), 3.09 (dt, *J* = 15.2, 7.8 Hz, 1H), 2.82 (dt, *J* = 14.5, 7.0 Hz, 1H), 2.17 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 147.3, 139.7, 136.7, 134.3, 129.3, 129.0, 128.9, 128.3, 127.0, 116.6, 93.8, 66.6, 38.2, 12.2.

HRMS (ESI) m/z calculated for $C_{16}H_{18}BrN_2$ $[M+H]^+$: 317.0648, found: 317.0647.

(E)-3,4,5-Tribromo-1-(1-phenylhexa-3,5-dien-1-yl)-1H-pyrazole (3ah)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2h** (45.3 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **3ah** (36.6 mg, 80% yield) as yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 7.41-7.26 (m, 5H), 6.33-6.02 (m, 2H), 5.60-5.34 (m, 2H), 5.12 (d, J = 16.4 Hz, 1H), 5.02 (d, J = 9.9 Hz, 1H), 3.29 (dt, J = 15.5, 8.2 Hz, 1H), 2.91 (dt, J = 13.8, 6.7 Hz, 1H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 138.7, 136.6, 134.6, 128.93, 128.90, 128.6, 128.4, 127.1, 116.9, 116.8, 99.9, 65.8, 38.1.

HRMS (ESI) m/z calculated for $C_{15}H_{14}Br_3N_2$ $[M+H]^+$: 458.8702, found: 458.8699.

(E)-1-(1-Phenylhexa-3,5-dien-1-yl)-1H-indazole (3ai)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2i** (17.7 mg, 0.15 mmol, 1.5 eq.) via general procedure B. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:15) furnished **3ai** (19.7 mg, 72% yield) as yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 7.93 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.42-7.21 (m, 6H), 7.13-7.00 (m, 1H), 6.32-6.00 (m, 2H), 5.61 (dd, J = 8.7, 6.7 Hz, 1H), 5.52 (dt, J = 14.4, 7.0 Hz, 1H), 5.09 (d, J = 16.0 Hz, 1H), 4.97 (d, J = 9.3 Hz, 1H), 3.42 (dt, J = 15.1, 7.6 Hz, 1H), 3.09 (dt, J = 14.2, 7.0 Hz, 1H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 148.7, 139.6, 136.7, 134.3, 129.3, 128.9, 128.4, 127.1, 126.0, 122.2, 121.8, 121.7, 120.4, 117.9, 116.7, 67.8, 38.6.

HRMS (ESI) m/z calculated for $C_{19}H_{19}N_2$ $[M+H]^+$: 275.1543, found: 275.1545.

(E)-1,3-Diphenyl-2-(1-phenylhexa-3,5-dien-1-yl)propane-1,3-dione (3aj)



The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **2j** (44.8 mg, 0.2 mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **3aj** (19.0 mg, 50% yield).


as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 7.7 Hz, 2H), 7.73 (d, *J* = 7.7 Hz, 2H), 7.60-7.38 (m, 4H), 7.33-7.05 (m, 7H), 6.11 (dt, *J* = 17.0, 10.2 Hz, 1H), 5.88 (dd, *J* = 15.1, 10.4 Hz, 1H), 5.69 (d, *J* = 10.3 Hz, 1H), 5.40 (dt, *J* = 14.8, 7.2 Hz, 1H), 5.12-4.69 (m, 2H), 4.05 (dt, 1H), 2.52 (t, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 194.9, 194.5, 140.9, 137.2, 137.0, 136.9, 133.7, 133.3, 133.2, 131.5, 129.0, 128.8, 128.6, 128.5, 128.4, 126.8, 115.7, 63.9, 47.1, 37.3.


HRMS (ESI) *m/z* calculated for C₂₇H₂₅O₂ [M+H]⁺: 381.1849, found: 381.1850.

General procedure C for synthesis of 5a-5k



General procedure C: A 10 mL dry tube equipped with a stir bar was charged with compound **1** (0.1 mmol, 1.0 eq.), **water** (0.5 mmol) or alcohols **4** (0.2 mmol, 2.0 eq.), Ga(OTf)₃ (30 mol% for the synthesis of **5a-5b**, **5e** and **5h-5k**; 50 mol% for the synthesis of **5c-5d**, **5f-5g**) and dry DCE (2.0 mL). The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, then 2.0 ml of water was added, and the reaction solution was extracted with ethyl acetate (3 x 5 mL), the combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel to afford the corresponding products (**5a-5k**).

(*E*)-1-Phenylhexa-3,5-dien-1-ol (**5a**)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5a** (11.3 mg, 65% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.44-7.26 (m, 5H), 6.49-6.04 (m, 2H), 5.69 (dt, *J* = 14.8, 7.3 Hz, 1H), 5.15 (d, *J* = 16.6 Hz, 1H), 5.03 (d, *J* = 9.9 Hz, 1H), 4.74 (t, *J* = 6.5 Hz, 1H), 2.55 (t, *J* = 7.2 Hz, 2H), 2.00 (s, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 144.0, 136.8, 134.6, 130.2, 128.6, 127.8, 125.9, 116.5, 73.8, 42.8.

HRMS (ESI) *m/z* calculated for C₁₂H₁₅O [M+H]⁺: 175.1117, found: 175.1120.

(*E*)-1-(*p*-Tolyl)hexa-3,5-dien-1-ol (**5b**)



The title compound was prepared from **1b** (18.8 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5b** (12.4 mg, 66% yield)


as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.35-7.14 (m, 4H), 6.53-6.03 (m, 2H), 5.68 (dt, *J* = 14.8, 7.0 Hz, 1H), 5.15 (d, *J* = 16.2 Hz, 1H), 5.03 (d, *J* = 10.2 Hz, 1H), 4.85-4.61 (m, 1H), 2.53 (t, *J* = 6.7 Hz, 2H), 2.35 (s, 3H), 1.96 (s, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 141.0, 137.4, 136.9, 134.4, 130.4, 129.3, 125.9, 116.3, 73.6, 42.7, 21.3.

The NMR data was similar with the reported literature.³

***(E)*-1-(2-Methoxyphenyl)hexa-3,5-dien-1-ol (5c)**




The title compound was prepared from **1d** (19.2 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5c** (11.5 mg, 60% yield) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.33 (dd, *J* = 7.5, 1.8 Hz, 1H), 7.28-7.21 (m, 1H), 6.96 (t, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 8.2 Hz, 1H), 6.32 (dt, *J* = 16.9, 10.3 Hz, 1H), 6.15 (dd, *J* = 15.1, 10.4 Hz, 1H), 5.74 (dt, *J* = 14.9, 7.3 Hz, 1H), 5.12 (d, *J* = 16.8 Hz, 1H), 5.04-4.91 (m, 2H), 3.85 (s, 3H), 2.67-2.48 (m, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 156.5, 137.1, 133.8, 131.8, 131.2, 128.5, 126.9, 120.8, 115.8, 110.5, 70.2, 55.4, 40.7.

The NMR data was similar with the reported literature.³

***(E)*-1-(2,4-Dimethylphenyl)hexa-3,5-dien-1-ol (5d)**




The title compound was prepared from **1e** (20.2 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5d** (12.3 mg, 61% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.36 (d, *J* = 7.8 Hz, 1H), 7.05 (d, *J* = 7.8 Hz, 1H), 6.96 (s, 1H), 6.48-6.06 (m, 2H), 5.73 (dt, *J* = 14.8, 7.3 Hz, 1H), 5.15 (d, *J* = 15.9 Hz, 1H), 5.02 (d, *J* = 9.9 Hz, 1H), 4.94 (dd, *J* = 7.7, 5.1 Hz, 1H), 2.57-2.40 (m, 2H), 2.32 (s, 3H), 2.30 (s, 3H), 1.88 (s, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 139.1, 137.0, 136.9, 134.4, 134.3, 131.3, 130.7, 127.1, 125.3, 116.3, 70.1, 41.6, 21.1, 19.1.

HRMS (ESI) *m/z* calculated for C₁₄H₁₉O [M+H]⁺: 203.1430, found: 203.1433.

***(E)*-1-(4-Chlorophenyl)hexa-3,5-dien-1-ol (5e)**




The title compound was prepared from **1h** (20.8 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5e** (11.0 mg, 53% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 7.37-7.24 (m, 4H), 6.41-6.23 (m, 1H), 6.22-6.07 (m, 1H), 5.64 (dt, *J* = 14.8, 7.4 Hz, 1H), 5.15 (d, *J* = 16.1 Hz, 1H), 5.04 (d, *J* = 9.9 Hz, 1H), 4.71 (t, *J* = 6.5 Hz, 1H), 2.59-2.41 (m, 2H), 2.08 (s, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 142.4, 136.7, 134.9, 133.3, 129.6, 128.7, 127.3, 116.7, 73.0, 42.8.

The NMR data was similar with the reported literature.³

***(E)*-1-(2-Bromophenyl)hexa-3,5-dien-1-ol (5f)**




The title compound was prepared from **1j** (25.2 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5f** (12.6 mg, 50% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 7.62-7.46 (m, 2H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.14 (t, *J* = 7.4 Hz, 1H), 6.64-5.97 (m, 2H), 5.77 (dt, *J* = 14.8, 7.3 Hz, 1H), 5.35-4.90 (m, 3H), 2.76-2.58 (m, 1H), 2.38 (dt, *J* = 15.2, 8.2 Hz, 1H), 2.13 (s, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 142.8, 136.8, 134.8, 132.8, 130.0, 129.0, 127.8, 127.4, 121.9, 116.6, 72.3, 41.0.

HRMS (ESI) *m/z* calculated for C₁₂H₁₄BrO [M+H]⁺: 253.0223, found: 253.0220.

***(E)*-1-(6-Bromobenzo[d][1,3]dioxol-5-yl)hexa-3,5-dien-1-ol (5g)**




The title compound was prepared from **1m** (29.6 mg, 0.1 mmol, 1 eq.) and **4a** (3.6 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:10) furnished **5g** (16.0 mg, 54% yield) as yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 7.05 (s, 1H), 6.96 (s, 1H), 6.50-6.07 (m, 2H), 5.97 (s, 2H), 5.74 (dt, *J* = 14.9, 7.3 Hz, 1H), 5.19 (d, 1H), 5.14-4.94 (m, 2H), 2.67-2.49 (m, 1H), 2.34 (dt, *J* = 15.1, 8.2 Hz, 1H), 2.10 (s, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 147.8, 136.8, 136.3, 134.7, 130.0, 116.6, 112.6, 112.1, 107.3, 101.9, 72.2, 41.2.

HRMS (ESI) *m/z* calculated for C₁₃H₁₄BrO₃ [M+H]⁺: 297.0121, found: 297.0125.

***(E)*-(1-Ethoxyhexa-3,5-dien-1-yl)benzene (5h)**




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **4b** (9.2 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **5h** (17.0 mg, 84% yield) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.43-7.21 (m, 5H), 6.29 (dt, *J* = 17.0, 10.3 Hz, 1H), 6.18-5.96 (m, 1H), 5.66 (dt, *J* = 14.8, 7.2 Hz, 1H), 5.08 (d, *J* = 17.0 Hz, 1H), 4.97 (d, *J* = 10.1 Hz, 1H), 4.25 (dd, *J* = 7.6, 5.8 Hz, 1H), 3.46-3.21 (m, 2H), 2.60 (dt, *J* = 14.5, 7.3 Hz, 1H), 2.41 (dt, *J* = 13.6, 6.6 Hz, 1H), 1.17 (t, *J* = 7.0 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 142.5, 137.2, 133.1, 131.2, 128.5, 127.6, 126.7, 115.6, 82.0, 64.3, 41.6, 15.4.

HRMS (ESI) m/z calculated for $\text{C}_{14}\text{H}_{19}\text{O}$ $[\text{M}+\text{H}]^+$: 203.1430, found: 203.1433.

(E)-(1-Isopropoxyhexa-3,5-dien-1-yl)benzene (5i)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **4c** (12.0 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **5i** (15.8 mg, 73% yield) as colorless oil.

^1H NMR (300 MHz, CDCl_3) δ 7.37-7.24 (m, 5H), 6.40-6.17 (m, 1H), 6.06 (dd, J = 15.2, 10.4 Hz, 1H), 5.66 (dt, J = 14.8, 7.2 Hz, 1H), 5.08 (d, J = 17.1 Hz, 1H), 4.96 (d, J = 10.1 Hz, 1H), 4.35 (dd, J = 7.8, 5.7 Hz, 1H), 3.58-3.37 (m, 1H), 2.54 (dt, J = 14.6, 7.4 Hz, 1H), 2.38 (dt, J = 13.8, 6.5 Hz, 1H), 1.14 (d, J = 6.0 Hz, 3H), 1.08 (d, J = 6.2 Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 143.3, 137.3, 133.0, 131.4, 128.4, 127.5, 126.7, 115.5, 79.3, 69.1, 42.0, 23.5, 21.4.

HRMS (ESI) m/z calculated for $\text{C}_{15}\text{H}_{21}\text{O}$ $[\text{M}+\text{H}]^+$: 217.1587, found: 217.1591.

(E)-(1-(tert-Butoxy)hexa-3,5-dien-1-yl)benzene (5j)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **4d** (14.8 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **5j** (13.8 mg, 60% yield) as colorless oil.

^1H NMR (300 MHz, CDCl_3) δ 7.38-7.26 (m, 5H), 6.30 (dt, J = 16.9, 10.2 Hz, 1H), 6.05 (dd, J = 15.2, 10.4 Hz, 1H), 5.67 (dt, J = 14.9, 7.3 Hz, 1H), 5.09 (d, J = 17.0 Hz, 1H), 4.97 (d, J = 10.1 Hz, 1H), 4.46 (dd, J = 8.1, 5.3 Hz, 1H), 2.54-2.24 (m, 2H), 1.11 (s, 9H).

^{13}C NMR (75 MHz, CDCl_3) δ 146.2, 137.4, 133.0, 132.1, 128.2, 126.8, 126.2, 115.4, 74.6, 74.5, 43.7, 28.8.

HRMS (ESI) m/z calculated for $\text{C}_{16}\text{H}_{23}\text{O}$ $[\text{M}+\text{H}]^+$: 231.1743, found: 231.1745.

(E)-(1-Phenoxyhexa-3,5-dien-1-yl)benzene (5k)




The title compound was prepared from **1a** (17.4 mg, 0.1 mmol, 1 eq.) and **4e** (18.8 mg, 0.2mmol, 2.0 eq.) via general procedure. Purified by silica gel column chromatography (eluent: EtOAc/PE = 1:20) furnished **5k** (16.5 mg, 66% yield) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, *J* = 6.8 Hz, 4H), 7.25 (d, *J* = 6.8 Hz, 1H), 7.17 (t, *J* = 7.9 Hz, 2H), 6.96-6.75 (m, 3H), 6.29 (dt, *J* = 16.9, 10.2 Hz, 1H), 6.12 (dd, *J* = 15.2, 10.4 Hz, 1H), 5.74 (dt, *J* = 14.8, 7.2 Hz, 1H), 5.18-5.06 (m, 2H), 4.99 (d, *J* = 10.0 Hz, 1H), 2.78 (dt, *J* = 14.7, 7.4 Hz, 1H), 2.60 (dt, *J* = 13.8, 6.3 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 158.2, 141.5, 137.1, 133.8, 130.2, 129.5, 129.4, 128.7, 127.7, 126.1, 120.9, 116.1, 80.0, 41.9.

HRMS (ESI) *m/z* calculated for C₁₈H₁₉O [M+H]⁺: 251.1430, found: 251.1437.

The preparation of the compound 6




The compound **3aa** (26.9 mg, 0.1 mmol) was dissolved in the solvent of DCE (2.0 mL), then styrene (8.0 equiv.) and the Grubbs II catalyst (15 mol %) was added. The reaction was heated to 100 °C stirred for 12 h, until the substrate was fully consumed (monitored by TLC). After complete consumption of the starting material, the mixture solution was quenched by H₂O (2 mL) and extracted with EtOAc (3 * 2 mL). The combined organic layer was washed with brine solution and dried over anhydrous Na₂SO₄, concentrated under reduced pressure and purified by silica gel column chromatography (EtOAc/PE = 1:10) to give (E)-1-(1,4-diphenylbut-3-en-1-yl)-4-nitro-1H-pyrazole **6** (23.0 mg, 72% yield) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 8.12 (s, 2H), 7.58-7.09 (m, 10H), 6.48 (d, *J* = 15.8 Hz, 1H), 6.00 (dt, *J* = 15.3, 7.2 Hz, 1H), 5.38 (t, *J* = 7.7 Hz, 1H), 3.37 (dt, *J* = 15.6, 8.1 Hz, 1H), 3.10 (dt, *J* = 14.1, 6.7 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 137.9, 136.7, 135.9, 134.2, 129.3, 129.2, 128.73, 128.70, 128.1, 127.8, 127.2, 126.3, 123.9, 67.9, 38.4.

HRMS (ESI) *m/z* calculated for C₁₉H₁₈N₃O₂ [M+H]⁺: 320.1394, found: 320.1399.

The preparation of the compound 7



The compound **3aa** (26.9 mg, 0.1 mmol) was dissolved in the solvent of THF (2.0 mL), then 2-Butene-1,4-diol (8.0 equiv.) and the Grubbs I catalyst (15 mol %) was added. The reaction was heated to 100 °C stirred for 12 h, until the substrate was fully consumed (monitored by TLC). After complete consumption of the starting material, the mixture solution was quenched by H₂O (2 mL) and extracted with EtOAc (3 * 2 mL). The combined organic layer was washed with brine solution and dried over anhydrous Na₂SO₄, concentrated under reduced pressure and purified by silica gel column


chromatography (EtOAc/PE = 1:5) to give (2E,4E)-7-(4-nitro-1H-pyrazol-1-yl)-7-phenylhepta-2,4-dien-1-ol **7** (17.3 mg, 58% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 8.09 (s, 1H), 7.46-7.26 (m, 5H), 6.31-5.96 (m, 2H), 5.88-5.65 (m, 1H), 5.60-5.42 (m, 1H), 5.30 (t, *J* = 7.7 Hz, 1H), 4.15 (d, *J* = 5.6 Hz, 2H), 3.24 (dt, *J* = 15.6, 8.1 Hz, 1H), 2.97 (dt, *J* = 14.2, 6.8 Hz, 1H), 1.40 (s, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 137.8, 135.9, 133.7, 132.2, 130.5, 129.3, 129.2, 128.0, 127.8, 127.2, 67.8, 63.3, 38.0.

HRMS (ESI) *m/z* calculated for C₁₆H₁₈N₃O₃ [M+H]⁺: 300.1343, found: 300.1340.

The preparation of the compound **8**




The compound **3aa** (26.9 mg, 0.1 mmol) was dissolved in the solvent of methanol (4.0 mL), Pd/C (15%wt, 5.5 mg) was added to the mixture solution, and the solution was then purged with hydrogen balloon and went 24 h under hydrogen balloon. Then, the reaction was filtered over a short path of Celite, concentrated in vacuo, and the crude mixture was purified by flash column chromatography (EtOAc/PE = 1/3) to give 1-(1-phenylhexyl)-1H-pyrazol-4-amine **8** (14.8 mg, 61% yield) as dark red oil.

¹H NMR (400 MHz, CDCl₃) δ 7.65-7.09 (m, 6H), 7.03 (s, 1H), 5.12 (t, *J* = 7.7 Hz, 1H), 2.63 (s, 2H), 2.43-2.25 (m, 1H), 2.16-2.01 (m, 1H), 1.28 (d, *J* = 12.0 Hz, 6H), 0.85 (t, *J* = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 141.4, 131.1, 128.8, 128.7, 127.8, 126.7, 117.6, 66.4, 35.2, 31.6, 26.3, 22.6, 14.1.

HRMS (ESI) *m/z* calculated for C₁₅H₂₂N₃ [M+H]⁺: 244.1808, found: 244.1814.

Synthesis method of enantioenriched vinyl cyclopropyl alcohol **1a**




According to the procedure of reported literature,⁴ to a dried 250 mL flask were added CH₂I₂ (20.0 mmol, 2.0 eq.) and CH₂Cl₂ (100 mL). After cooling to 0 °C, Et₂Zn (1 M in hexane, 12.5 mmol, 1.25 eq.) was added. The resulting mixture was stirred at this temperature for 30 min. To another flask were added 3-Phenyl-2-propen-1-ol (**I**) (1.34 g, 10.0 mmol, 1.0 eq.), (1*S*,2*S*)-**L** (270.4 mg, 1.0 mmol, 0.1 eq.) and CH₂Cl₂ (30 mL). After cooling to 0 °C, Et₂Zn (1 M in hexane, 12.5

mmol, 1.25 eq.) was added. The resulting mixture was stirred at this temperature for 30 min. This reaction mixture was then added to the reaction mixture in the 250 mL flask. After stirred at 0 °C for 30 min, the resulting mixture was allowed to warm to room temperature and then stirred for 18 h. Then, the reaction mixture was quenched with sat. aq. NH₄Cl and 1 M aq. HCl. The organic layer was separated. The aqueous layer was then extracted with CH₂Cl₂ (2*100 mL). The combined organic layer was dried over MgSO₄ and concentrated in vacuo. The residue was direct used without further purification. To a solution of compound (10.0 mmol) in CH₂Cl₂ (25 mL) was added PCC (15.0 mmol, 1.5 eq.) at room temperature under Ar atmosphere. After 1 h, the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel to afford **III** as colorless oil.


To a flame dried flask was cooled to 0 °C and charged with **III** (1.24g, 8.5 mmol, 1.0 eq.) and dry THF, the flask was backfilled with argon gas. Then, vinylmagnesium chloride (1.0 M in THF solution, 17.0 mmol, 2.0 eq.) was slowly added to the above solution. Then, the mixture was stirred at 0 °C for 1 h (monitored by TLC) and quenched with saturated aq. NH₄Cl (30 mL). The aqueous layer was extracted with EtOAc and the organic phase was dried with Na₂SO₄, filtered and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel to give the enantioenriched diastereoisomer **1a/1a'** = 1:1. Compound **1a** (591.6 mg, 40% yield) and **1a'** (591.6 mg, 40% yield) as colorless oil.

HPLC spectra of chiral **1a** (Daicel Chiralpak IB column (hexane/iPrOH = 95:5), flow rate: 1.0 mL/min, λ = 215 nm, t_R(major) = 7.70 min, t_R(minor) = 8.28 min. ee = 58%)



Peak Name	RT [min]	Type	width [min]	Area [mAU*s]	Height [mAU]	Area ratio %
1	7.687	VV R	0.2597	1923.05945	111.99230	49.8778
2	8.259	VB	0.2886	1932.48340	100.83273	50.1222


Rac-1a



Peak Name	RT [min]	Type	width [min]	Area [mAU*s]	Height [mAU]	Area ratio %
1	7.696	BV	0.2298	1.23717e4	850.12811	78.9960
2	8.277	VB	0.2383	3289.46387	215.21815	21.0040

Chiral-1a


Stereospecific reaction with enantioenriched vinyl cyclopropyl alcohol **1a** with **2a**



The compound chiral **1a** (17.5 mg, 0.1 mmol, 58% ee) was dissolved in dry DCE (2 mL), and then the 3-nitropyrrole **2a** (17.0 mg, 0.15 mmol, 1.5 eq.) and Yb(OTf)₃ (50 mol%, 0.5 eq.) were added to the solution. The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, then 2.0 ml of water was added, and the reaction solution was extracted with ethyl acetate (3 * 5 mL), the combined organic layers were dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure. The


remaining residue was purified by column chromatography on silica gel to afford the corresponding products chiral **3aa** in 80% yield. ¹H NMR was similar with the compound **3aa**.

HPLC spectra of **3aa** (Daicel Chiralpak IB column (hexane/iPrOH) = 95:5, flow rate: 1.0 mL/min, λ = 215 nm, t_R (major) = 14.32 min, t_R (minor) = 18.38 min. ee = 31%)



Peak Name	RT [min]	Type	width [min]	Area [mAU*s]	Height [mAu]	Area ratio %
1	14.151	VB R	0.2723	1.75550e4	962.76953	49.9793
2	18.224	VB R	0.3372	1.75695e4	780.72186	50.0207

Rac-3aa






Peak Name	RT [min]	Type	width [min]	Area [mAU*s]	Height [mAu]	Area ratio %
1	14.321	VB R	0.2756	7577.15625	414.42847	65.6356
2	18.384	VB R	0.3349	3967.11499	177.14307	34.3644

Chiral-3aa


References


1. a) Qu, Z.; Shi, W.; Wang, J. *Chin. Chem. Lett.* **2002**, 13, 1033-1036. b) Toy, P. H.; Newcomb, M.; Hollenberg, P. F. *J. Am. Chem. Soc.* **1998**, 120, 7719-7729. c) Kim, H. Y.; Salvi, L.; Carroll, P. J.; Walsh, P. J. *J. Am. Chem. Soc.* **2010**, 132, 402-412.
2. a) H. Y. Kim, L. Salvi, P. J. Carroll, P. J. Walsh, *J. Am. Chem. Soc.* **2010**, 132, 402-412. b) R. Infante, J. Nieto, C. Andrés, *Org. Biomol. Chem.*, **2014**, 12, 345-354.
3. J. Liu, B. Su, M. Chen. *Org. Lett.* **2021**, 23, 6035-6040.
4. S. E. Denmark and S. P. O'Connor, *J. Org. Chem.* **1997**, 62, 3390-3401







1a








1a'








1a'














1c








1c













1e







1e







1f







1f








1g











1g























1j











1j








































3aa



















































3ga






















— 62.80

















3ka













3ma







3ma








3na







3na















3ab















































3ah










3ai







3aj







3aj








5a








5a













5c







5c





5d






5d


139.14
137.03
136.93
134.43
134.30
131.31
130.72
127.10
125.27
116.28

77.58
77.16
76.74
70.10


41.59


21.11
19.12







5e







5e








5f







5f










5g








5h







5h










5i








5j








5j













6







6







7







7





8





8

